LIVE TV
LIVE TV
LIVE TV
Home > World > BRIEF-Vicore Pharma Holding AB Phase 2B Aspire Trial Of Buloxibutid In Ipf Passes Pre-Planned Futility Analysis, On Track For Mid-2027 Topline Results

BRIEF-Vicore Pharma Holding AB Phase 2B Aspire Trial Of Buloxibutid In Ipf Passes Pre-Planned Futility Analysis, On Track For Mid-2027 Topline Results

Written By:
Published: October 23, 2026 03:53:05 IST

Add NewsX As A Trusted Source

Oct 22 (Reuters) – Vicore Pharma Holding AB: * VICORE PHARMA HOLDING AB: PHASE 2B ASPIRE TRIAL OF BULOXIBUTID IN IPF PASSES PRE-PLANNED FUTILITY ANALYSIS, ON TRACK FOR MID-2027 TOPLINE RESULTS *

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

RELATED News

LATEST NEWS